One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Aminoglycosides Market

[ 英語タイトル ] Aminoglycosides Market - Growth, Trends, and Forecasts (2020 - 2025)

Product Code : MDHC0089068
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 112
Category : Healthcare and Pharmaceuticals
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Cipla Limited
- Pfizer Inc.
- Allergan plc
- Novartis AG
- Johnson & Johnson
- Medico Remedies Pvt. Ltd
- Bristol Myers Squibb Company
- Vega Pharma Ltd.
- Xian Wison Biological Technology Co., Ltd.
- Yi Chang Veterinary Medicine Factory

[Report Description]

The global aminoglycosides market size is expected to witness a growth of over 4.3% CAGR over the forecast period, owing to the increasing burden of animal disease outbreaks leading to high utilization of antibiotics.

Moreover, this class of antibiotics is found to be effective even when bacterial inoculum is large, and are frequently used as a second line of defense against basic infection resistant to basic antibacterials. Additionally, reduction in the prescription rate of aminoglycoside antibiotics due to side effects associated with the usage of these drugs that include severe ototoxicity, nephrotoxicity, and neuromuscular blockade is expected to affect the market growth negatively.

Key Market Trends

Gentamicin Accounted for the Largest Share in the Global Market

- Gentamicin is the agent of choice for major bacterial infections amongst others. Tobramycin has been found to be slightly more effective against Pseudomonas aeruginosa infections.
- Amikacin and gentamicin find maximum usage in veterinary medicine. Gentamicin is indicated in perinatal complications, sepsis, acute/chronic renal disease, labor or neonatal complications, diabetes, and UTI/pyelonephritis.
- Gentamicin forms the first line of treatment for many disorders in both developing and developed markets. Its usage is particularly high in developing regions where older gentamicin is a cost-effective and efficacious drug for many infectious diseases. Thus, its demand is consistently growing for a range of bacterial infection related diseases, with several players using it in combinations.
- Moreover, neomycin, streptomycin, gentamicin, kanamycin, tobramycin, amikacin, and others are included in the product categorization of aminoglycosides. Streptomycin is a first level antibacterial used for the treatment of tuberculosis. Aminoglycosides used in the treatment of MDR-TB include kanamycin capreomycin and amikacin.

North America dominates the global aminoglycoside market

Noth America saminoglycoside market anticipated to have significant share over the forecast period. The growth is attributed to increasing incidence of bacterial infections. The growing demand for early-phase diagnosis and treatment of infectious diseases is expected to drive the growth of the aminoglycoside market in North America. According to the 2017 data published by the Centres for Disease Control & Prevention (CDC), in 2016 the total approximate number of visits in the US, to physician offices for infectious diseases was 16.8 million. The increasing incidence rate and high patient-visit volume for infectious diseases is the primary driver for North America's largest share in Aminoglycoside market

Europe is the second-largest market for aminoglycoside in terms of value as there are favourable government policies regarding health care infrastructure and awareness of the population.

Competitive Landscape

The market studied is composed of a large number of players and includes both small and large pharmaceutical manufacturers. Additionally, the increasing antibiotic resistance has prompted many early-stage biotechnology enterprises to enter this market. The expiry of patent exclusivity has led to large scale generic manufacturing of aminoglycosides, particularly in the developing region of Asia-Pacific. The key market players include Pfizer Inc, Johnson and Johnson, Allergan Plc Cipla and BMS among others.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Incurable Status of the Disease
4.2.2 Global increase in Aging Population
4.2.3 Increasing Prevalence of Brain Disorders
4.3 Market Restraints
4.3.1 Adverse and Toxic Reactions Associated with Aminoglycosides
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 Product
5.1.1 Neomycin
5.1.2 Tobramycin
5.1.3 Gentamicin
5.1.4 Amikacin
5.1.5 Paromomycin
5.1.6 Streptomycin
5.1.7 Kanamycin
5.1.8 Other Aminoglycosides
5.2 Route of Administration
5.2.1 Parenteral
5.2.2 Intra-mammary
5.2.3 Topical
5.2.4 Oral
5.3 Application
5.3.1 Veterinary
5.3.2 Skin Infection
5.3.3 Respiratory Diseases
5.3.4 UTI & Pelvic Diseases
5.3.5 Other Diseases
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Cipla Limited
6.1.2 Pfizer Inc.
6.1.3 Allergan plc
6.1.4 Novartis AG
6.1.5 Johnson & Johnson
6.1.6 Medico Remedies Pvt. Ltd
6.1.7 Bristol Myers Squibb Company
6.1.8 Vega Pharma Ltd.
6.1.9 Xian Wison Biological Technology Co., Ltd.
6.1.10 Yi Chang Veterinary Medicine Factory




Recommended reports